Catabasis Pharmaceuticals, Inc. (CATB) Social Stream
Catabasis Pharmaceuticals Inc (CATB) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering CATB.
| Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|
| 4 | $36 | $13 | $23.75 | $8.54 | 178.1% |
Over the past 16 months, CATB's average upside potential has been 458.38%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-09-09 | 4 | 36 | 13.0 | 23.75 | 8.54 | 178.1% |
| 2021-09-04 | 4 | 36 | 13.0 | 23.75 | 9.53 | 149.21% |
| 2021-08-28 | 3 | 36 | 13.0 | 26.33 | 9.36 | 181.3% |
| 2021-08-14 | 2 | 6 | 5.0 | 5.50 | 1.34 | 310.45% |
| 2021-08-07 | 2 | 6 | 5.0 | 5.50 | 1.55 | 254.84% |
| 2021-08-05 | 2 | 6 | 5.0 | 5.50 | 1.52 | 261.84% |
| 2021-08-01 | 2 | 6 | 5.0 | 5.50 | 1.63 | 237.42% |
| 2021-07-24 | 2 | 6 | 5.0 | 5.50 | 1.63 | 237.42% |
| 2021-07-17 | 2 | 6 | 5.0 | 5.50 | 1.65 | 233.33% |
| 2021-07-10 | 2 | 6 | 5.0 | 5.50 | 2.01 | 173.63% |
| 2021-07-03 | 2 | 6 | 5.0 | 5.50 | 2.08 | 164.42% |
| 2021-06-26 | 2 | 6 | 5.0 | 5.50 | 2.15 | 155.81% |
| 2021-06-13 | 2 | 6 | 5.0 | 5.50 | 2.07 | 165.7% |
| 2021-06-05 | 2 | 6 | 5.0 | 5.50 | 2.01 | 173.63% |
| 2021-05-22 | 2 | 6 | 5.0 | 5.50 | 1.92 | 186.46% |
| 2021-05-15 | 2 | 6 | 5.0 | 5.50 | 1.78 | 208.99% |
| 2021-05-08 | 1 | 5 | 5.0 | 5.00 | 1.96 | 155.1% |
| 2021-04-25 | 1 | 5 | 5.0 | 5.00 | 2.25 | 122.22% |
| 2021-04-17 | 1 | 5 | 5.0 | 5.00 | 2.24 | 123.21% |
| 2021-04-10 | 1 | 5 | 5.0 | 5.00 | 2.71 | 84.5% |
| 2021-04-03 | 1 | 5 | 5.0 | 5.00 | 2.87 | 74.22% |
| 2021-03-20 | 1 | 5 | 5.0 | 5.00 | 3.45 | 44.93% |
| 2021-03-13 | 1 | 5 | 5.0 | 5.00 | 3.37 | 48.37% |
| 2021-03-06 | 1 | 24 | 24.0 | 24.00 | 2.81 | 754.09% |
| 2021-02-27 | 1 | 24 | 24.0 | 24.00 | 2.88 | 733.33% |
| 2021-02-20 | 1 | 24 | 24.0 | 24.00 | 3.56 | 574.16% |
| 2021-02-13 | 1 | 24 | 24.0 | 24.00 | 3.52 | 581.82% |
| 2021-02-06 | 1 | 24 | 24.0 | 24.00 | 3.30 | 627.27% |
| 2021-01-30 | 1 | 24 | 24.0 | 24.00 | 4.15 | 478.31% |
| 2021-01-23 | 1 | 24 | 24.0 | 24.00 | 2.73 | 779.12% |
| 2021-01-16 | 1 | 24 | 24.0 | 24.00 | 2.61 | 819.54% |
| 2021-01-09 | 1 | 24 | 24.0 | 24.00 | 2.36 | 916.95% |
| 2021-01-02 | 1 | 24 | 24.0 | 24.00 | 2.14 | 1021.5% |
| 2020-12-26 | 1 | 24 | 24.0 | 24.00 | 2.25 | 966.67% |
| 2020-12-19 | 1 | 24 | 24.0 | 24.00 | 2.16 | 1011.11% |
| 2020-12-10 | 1 | 24 | 24.0 | 24.00 | 1.93 | 1143.52% |
| 2020-12-07 | 1 | 24 | 24.0 | 24.00 | 1.90 | 1163.16% |
| 2020-11-28 | 1 | 24 | 24.0 | 24.00 | 1.59 | 1409.43% |
| 2020-10-30 | 2 | 24 | 11.5 | 17.75 | 1.34 | 1224.63% |
| 2020-10-23 | 2 | 24 | 15.0 | 19.50 | 5.82 | 235.05% |
| 2020-09-28 | 3 | 60 | 15.0 | 33.00 | 6.24 | 428.85% |
| 2020-05-24 | 2 | 60 | 15.0 | 37.50 | NA | NA% |
CATB Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.12 | 3 | 1 | 0 | 0 | 0 | 4 |
The Trend in the Broker Recommendations
CATB's average broker recommendation rating improved by 0.67 over the prior 123 days.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- The variance in analysts' estimates of CATB is less than 5.59999999999999% of all US stocks.
- CATB has a greater upside potential (average analyst target price relative to current price) than 89.38% of all US stocks.
- CATB has a higher number of analysts covering the stock than 84.4% of stocks in the micro market cap category.
- The average analyst price target of CATB is higher than 81.8% of stocks in the micro market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Catabasis Pharmaceuticals Inc are GRTX, SQZ and AVEO.
What is the outlook for CATB? Use POWR Ratings for clearer insight into price direction.